DefEYE Gains ExSight Ventures Investment for Ocular Biologics

DefEYE, a developer of regenerative biologic technologies for ophthalmology, has announced an investment from ExSight Ventures to support the advancement and commercialization of its decellularized placental-based tissue platform. The technology is designed for use in ocular surface disease and ocular surgical management, including procedures such as pterygium surgery.

According to the announcement, the platform aims to offer a portfolio of decellularized biologic solutions to enhance treatment outcomes across a range of anterior segment conditions.

ExSight Ventures, an ophthalmology-focused investment firm, has characterized DefEYE’s biologic approach as an innovative entry into the ocular biologics space. Despite initial skepticism, the firm cited positive clinical feedback as a key factor in the decision to invest.

“ExSight’s investment defies our initial skepticism of the technology and the market,” said Firas Rahhal, cofounder at ExSight Ventures. “Feedback pointed to better clinical outcomes, improved patient experience, and consequently, growing adoption.”

Strategic Partnership to Support Commercial Expansion

DefEYE’s chief executive officer, Rob Sambursky, MD, emphasized the strategic alignment between the two companies:

“ExSight Ventures’ deep knowledge and long-standing commitment to advancing innovation in the ophthalmic space make them an ideal strategic partner for DefEYE.”

He added that the investment will help accelerate the adoption of regenerative therapies that aim to improve both ocular surface disease management and surgical outcomes.

Terms of the Investment Remain Undisclosed

While the companies did not release specific financial terms, both parties confirmed that the funding will be directed toward commercial growth and platform expansion, reinforcing DefEYE’s position in the emerging field of ocular biologics.